Patient engagement in medicines development
4 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- FORUM DES PATIENTS EUROPEENS
European patient advocacy NGO embedding structured patient engagement into clinical trials, health data governance, and personalised medicine research.
“Core expertise demonstrated across PARADIGM (coordinated), PREFER, ADAPT-SMART, EU-PEARL, EFOEUPATI, Gravitate-Health, and CORE-MD — all focused on embedding patient perspectives in drug and device lifecycle.”
PrimaryBE17 projects - THE SYNERGIST
Brussels-based patient engagement and medication safety specialist contributing to major European health research and pharmacovigilance consortia.
“Central theme across PARADIGM (meaningful patient engagement), Gravitate-Health (patient empowerment with health information), and SHARE4RARE (collective intelligence from patient communities).”
PrimarySMEBE5 projects - EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE
Brussels-based NGO advancing patient engagement, clinical trial ethics, and pharmacovigilance standards across European health research.
“PARADIGM (€198K, largest project) focused on patient dialogues in medicines generation, and EFOEUPATI sustained the EUPATI patient engagement platform.”
PrimaryBE4 projects - AGENZIA ITALIANA DEL FARMACO
Italy's national medicines regulatory authority, contributing pharmaceutical approval expertise and regulatory science to European health research consortia.
“PARADIGM focused on advancing patient participation in research and dialogue around medicines development.”
IT3 projects